Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus‐seronegative liver transplant recipients of cytomegalovirus‐seropositive donor allografts
Nina Singh, Cheryl Wannstedt, Lois Keyes, Debra Mayher, Lisa Tickerhoof, Mohamed Akoad, Marilyn M. Wagener, Thomas V. Cacciarelli – 30 January 2008 – The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient‐negative/donor‐positive (R−/D+) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institution since July 2001, 36 (19.2%) belonged to the R−/D+ group.